WallStreetZenWallStreetZen

NASDAQ: BIIB
Biogen Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Biogen earnings were $1.5B for the trailing 12 months ending Jun 30, 2025, with 31.5% growth year over year. The latest BIIB earnings report on Jun 30, 2025 announced Q2 2025 earnings of $634.8M, up 164% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BIIB reported annual earnings of $1.6B, with 40.6% growth. The next BIIB earnings date is Oct 29, 2025.

BIIB past earnings growth

How has BIIB's earnings growth performed historically?

Company
31.49%
Industry
49.9%
Market
34.43%
BIIB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BIIB's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance
BIIB's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

BIIB earnings history

Current Revenue
$10.0B
Current Earnings
$1.5B
Current Profit Margin
15.3%
BIIB's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

BIIB Return on Equity

Current Company
9%
Current Industry
60%
Current Market
30.7%
BIIB's Return on Equity (9%)... subscribe to Premium to read more.
High Return on Equity Performance

BIIB undefined

Current Company
5.4%
Current Industry
10.6%
BIIB is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when BIIB announces earnings.

BIIB undefined

Current Company
7.15%
Current Industry
18.3%
BIIB's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BIIB vs General Drug Manufacturer Stocks

TickerEBITDAEarningsY/Y EarningsEPS
BIIB$2.61B$1.53B-21.06%$10.48
GRFS$1.71B$174.36M-25.16%$0.26
OGN$1.50B$700.00M-20.75%$2.71
AMRN-$94.40M-$103.59MN/A-$5.00
SCLX-$68.46M-$122.99MN/A-$10.73
View Top General Drug Manufacturer Stocks

BIIB earnings dates

Next earnings date
Oct 29, 2025

Biogen Earnings Reports & History FAQ

What were Biogen's earnings last quarter?

On BIIB's earnings call on Invalid Date, Biogen (NASDAQ: BIIB) reported Q2 2025 earnings per share (EPS) of $4.33, up 7.98% year over year. Total BIIB earnings for the quarter were $634.80 million. In the same quarter last year, Biogen's earnings per share (EPS) was $4.01.

If you're new to stock investing, here's how to buy Biogen stock.

When does Biogen report earnings?

The next BIIB earnings call is Invalid Date. Add BIIB to your watchlist to be reminded of Biogen's next earnings date.

Is Biogen profitable or losing money?

As of the last Biogen earnings report, Biogen is currently profitable. Biogen's net profit (also called net income) for the twelve months ending Jun 30, 2025 was $1.53 billion, a 32.1% increase year over year.

What was BIIB's earnings growth in the past year?

As of Biogen's earnings date in Invalid Date, Biogen's earnings has grown 31.49% year over year. This is 18.41 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 49.9%. BIIB earnings in the past year totalled $1.53 billion.

What are Biogen's earnings expectations?

The current EPS estimate for Biogen's earnings report in Invalid Date is $3.85.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.